Page last updated: 2024-08-05 12:41:50
vitamin D
Any member of a group of fat-soluble hydroxy seco-steroids that exhibit biological activity against vitamin D deficiency. Vitamin D can be obtained from sun exposure, food and supplements and is biologically inactive and converted into the biologically active calcitriol via double hydroxylation in the body.
ChEBI ID: 27300
Members (12)
| Member | Definition | Role |
|---|
| (1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol | | (1R,3S)-5-[2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol |
| 1,25-dihydroxy-24-oxo-16-ene-vitamin d3 | | 1,25-Dihydroxy-24-oxo-16-ene-vitamin D3 |
| 1,25-dihydroxyergocalciferol | A hydroxycalciol that is vitamin D2 bearing additional hydroxy substituents at positions 1alpha and 25. | 1alpha,25-dihydroxyvitamin D2 |
| 1,25-dihydroxyvitamin d3-26,23-lactone | | 1,25-Dihydroxyvitamin D3-26,23-lactone |
| 24-hydroxyvitamin d2 | | 24-hydroxyvitamin D2 |
| 25-hydroxyvitamin d 2 | A hydroxycalciol that is vitamin D2 in which the hydrogen at position 25 has been replaced by a hydroxy group. | 25-hydroxyvitamin D2 |
| carcinomedin | | Carcinomedin |
| tei 9647 | | (23S)-1-hydroxy-25,27-didehydrovitamin D3 26,23-lactone |
| vitamin d 2 | A vitamin D supplement and has been isolated from alfalfa. | vitamin D2 |
| vitamin d3 sulfoconjugate | | Vitamin D3 sulfoconjugate |
| zk 168281 | | ZK 168281 |
| zk159222 | | ZK 159222 |
Research
Studies (3,671)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|
| pre-1990 | 1,681 (45.79) | 18.7374 |
| 1990's | 249 (6.78) | 18.2507 |
| 2000's | 494 (13.46) | 29.6817 |
| 2010's | 1,085 (29.56) | 24.3611 |
| 2020's | 162 (4.41) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|
| Trials | 413 (9.47%) | 5.53% |
| Reviews | 340 (7.80%) | 6.00% |
| Case Studies | 214 (4.91%) | 4.05% |
| Observational | 28 (0.64%) | 0.25% |
| Other | 3,366 (77.18%) | 84.16% |